BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment
Nov 2, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. The company announced that the first patient in Europe has been enrolled in the study and has started receiving dosages. Eventually the company plans to have 68 sites opened for the ongoing potentially pivotal global trial; currently 29 clinical sites have been identified in the United States, Italy, France, Spain and Switzerland. According to the announcement, a preplanned, nonbinding futility analysis will be performed after an estimated 30% to 50% of all planned patients have completed the primary endpoint at six months. “Our team has worked tirelessly to expand the presence of our clinical trial for Berubicin on a global scale,” said CNS Pharmaceuticals CEO John Climaco in the press release. “To have enrolled and dosed our first patient in France shortly after the opening the site is a noteworthy accomplishment and a testament to our team’s dedication to drive the program forward. I am pleased with the progress made and remain committed to building on this momentum. We expect to enroll and dose additional patients across our clinical trial sites in Europe and advance toward the much-anticipated inflection point which is the interim analysis.”
To view the full press release, visit https://ibn.fm/zkGsX
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer.
Additionally, CNS Pharmaceuticals is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain, pancreatic and ovarian cancers as well as lymphomas. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
Palace rejects Erice’s presidential pork tag on local gov’t support fund
MANILA, Philippines — Malacañang on Wednesday dismissed Caloocan City Rep. Edgar Erice’s description of the almost P60-billion Local Government Support Fund (LGSF) as a “presidential pork barrel,” calling it an attempt to stir controversy. Palace Press Officer Claire Castro said Erice was free to challenge the legality of the LGSF before the Supreme Court but
Diokno: Prosec’s job not easier despite conviction vote ruling
MANILA, Philippines — Even if the Senate Impeachment Court has ruled to allow a lower number of votes to convict Vice President Sara Duterte, the job of the prosecution panel would not be easier as there are no changes to its role of presenting evidence, Akbayan party-list Rep. Chel Diokno said. Diokno, a member of the House
Almost P300,000 ‘shabu’ seized in Ilocos region operations
CALASIAO, Pangasinan — The police in the Ilocos region confiscated a total of 41.82 grams of suspected shabu worth an estimated P297,976 in a series of anti-illegal drugs operations in four provinces on last Tuesday, Sept. 22 The operations were conducted in Pangasinan, La Union, Ilocos Norte and Ilocos Sur, with Pangasinan accounting for the
Defense: Raising modified voting threshold to SC ‘real possibility’
MANILA, Philippines — Vice President Sara Duterte’s defense team on Wednesday said raising the recent ruling modifying the two-thirds conviction threshold before the Supreme Court (SC) is a “real possibility.” However, Defense spokesperson Atty. Michael Poa said this would still depend on their discussions with Duterte. READ: Senate impeach court reduces conviction threshold “‘Yung pag-akyat
NBI clearance center opens in Kabankalan, Negros Occidental
MANILA, Philippines — The National Bureau of Investigation (NBI) has opened a new clearance center in Kabankalan, Negros Occidental. In a press release on Wednesday, the bureau said the facility aims to enhance additional accessibility to its services. Inaugurated on Sept. 8, the new outlet is located at the Old Public Market in Barangay 4.
Palace open to amendments to anti-espionage law, says Castro
MANILA, Philippines — President Ferdinand Marcos Jr. is open to amendments to the anti-espionage law, which seeks to expand the scope of the existing law, Palace Press Officer Claire Castro said. The House approved on third and final reading House Bill 9642, or the proposed “New Espionage Act,” after gaining 247 affirmative votes, 10 negative votes, and no abstentions. The
Mendoza tells Senate: Many erring BIR personnel charged over LOA abuses
MANILA, Philippines — Many erring personnel of the Bureau of Internal Revenue (BIR) have been investigated and charged in connection with alleged abuses linked to the issuance of letters of authority (LOAs), according to BIR Commissioner Charlito Martin Mendoza. Mendoza mentioned this in response to Sen. JV Ejercito’s query at a budget hearing in the Senate on
Sandigan orders ex-Iriga mayor’s arrest over P31M malversation case
IRIGA CITY, CAMARINES SUR — Former Iriga City Mayor Madelaine Arlene Yorobe Alfelor has been detained while a second former city official was arrested on Tuesday (September 22). These action happened on the strength of an arrest warrant issued by the Fourth Division of the Sandiganbayan over the alleged 2022 malversation of P31 million in
‘Very strong El Niño’ to persist in PH until early 2027 – Pagasa
MANILA, Philippines — A very strong El Niño is likely to emerge between September and December 2026 and may continue until the first half of 2027, the state weather bureau said on Wednesday. Philippine Atmospheric, Geophysical and Astronomical Services Administration (Pagasa) Climate Monitoring and Prediction Section chief Ana Liza Solis said that based on climate
Palace: Jonvic Remulla may be called out over incorrect asylum claim
MANILA, Philippines — Malacañang on Wednesday said Interior Secretary Jonvic Remulla may be called out over his incorrect pronouncement about former presidential spokesperson Harry Roque’s asylum bid. On Tuesday evening, Remulla admitted that he was wrong when he earlier announced that Roque’s asylum bid had been rejected, saying the correct status was that the application remained
From fingerlings to harvest: Apayao livelihood program boosts incomes
BAGUIO CITY — For 15 farmers and fisherfolk in Luna, Apayao, a 400-square-meter fishpond is becoming more than a source of tilapia. It is a step toward building a livelihood they can sustain on their own. The ST Tilapia Productions Association harvested its first batch of fish Sept. 3, yielding 57.8 kilograms and P9,826 in gross
CICC extends Reddit’s deadline to set up PH presence
MANILA, Philippines — The Cybercrime Investigation and Coordinating Center (CICC) on Wednesday allowed online platform Reddit to establish a presence in the country beyond the initial 24-hour deadline in a bid to strengthen cooperation. The move follows the CICC’s earlier directive to Reddit and Discord to set up offices in the country as part of
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.